Ligand regulatory update

LGND submitted an NDA to the FDA and requested priority review status for its Targretin bexarotene capsules to treat early-stage cutaneous T cell lymphoma (CTCL) in patients who have not tolerated other therapies; patients with refractory or persistent early stage CTCL; and patients with refractory advanced stage CTCL. ...